Cayd Biotech

Cayd Biotech (卡尤迪生物) is a molecular diagnostics company in FreeS Fund's (峰瑞资本) portfolio, listed among the fund's high-growth innovation bets alongside XtalPi, Patpat and others . The most substantive detail in elsewhere's corpus comes from a FreeS Fund piece on biomedical trends: Cayd applied its core molecular diagnostics technology to nucleic acid testing and became the developer of China's first approved rapid nucleic acid testing system, playing a notable role in the global pandemic response . It also appears among FreeS-backed companies co-organizing the fund's 2023 China-US venture summit .

Beyond that, elsewhere's corpus doesn't carry a fuller profile — no founding date, team, or funding-round details are covered. Note that several similar-sounding names in the material (YolTech Therapeutics, for instance) are different companies entirely.